Bristol-Myers Squibb Co (BMY)
58.87
+0.64
(+1.10%)
USD |
NYSE |
Nov 22, 16:00
58.87
0.00 (0.00%)
After-Hours: 20:00
Bristol-Myers Squibb Revenue (Annual): 45.01B for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 45.01B |
December 31, 2022 | 46.16B |
December 31, 2021 | 46.38B |
December 31, 2020 | 42.52B |
December 31, 2019 | 26.14B |
December 31, 2018 | 22.56B |
December 31, 2017 | 20.78B |
December 31, 2016 | 19.43B |
December 31, 2015 | 16.56B |
December 31, 2014 | 15.88B |
December 31, 2013 | 16.38B |
December 31, 2012 | 17.62B |
December 31, 2011 | 21.24B |
December 31, 2010 | 19.48B |
December 31, 2009 | 18.81B |
December 31, 2008 | 17.72B |
December 31, 2007 | 19.35B |
December 31, 2006 | 17.26B |
December 31, 2005 | 18.60B |
Date | Value |
---|---|
December 31, 2004 | 19.38B |
December 31, 2003 | 18.65B |
December 31, 2002 | 18.11B |
December 31, 2001 | 17.99B |
December 31, 2000 | 18.22B |
December 31, 1999 | 16.88B |
December 31, 1998 | 15.06B |
December 31, 1997 | 16.70B |
December 31, 1996 | 15.06B |
December 31, 1995 | 13.77B |
December 31, 1994 | 11.98B |
December 31, 1993 | 11.41B |
December 31, 1992 | 11.16B |
December 31, 1991 | 11.16B |
December 31, 1990 | 10.30B |
December 31, 1989 | 9.189B |
December 31, 1988 | 8.558B |
December 31, 1987 | 7.558B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
26.14B
Minimum
2019
46.38B
Maximum
2021
41.24B
Average
45.01B
Median
2023
Revenue (Annual) Benchmarks
Johnson & Johnson | 85.16B |
Eli Lilly and Co | 34.12B |
Merck & Co Inc | 60.12B |
Pfizer Inc | 58.50B |
AbbVie Inc | 54.32B |